판정행렬을 기반한 일체형 PET-MRI의 폐암 진단 유용성 평가
Evaluation of Usefulness for Diagnosis of Lung Cancer on Integrated PET-MRI Using Decision Matrix
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
The results of empirical researches on the diagnosis of lung cancer are insufficient, so it is limited to objectively judge the clinical possibility and utilization according to the accuracy of diagnosis. Thus, this study retrospectively analyzed the lung cancer diagnostic performance of PET-MRI (Positron Emission Tomography-Magnetic Resonance Imaging) by using the decision matrix. This study selected and experimented total 165 patients who received both hematological CEA (Carcinoembryonic Antigen) test and hybrid PET-MRI (18F-FDG, 5.18 MBq/㎏ / Body TIM coil. VIVE-Dixon). After setting up the result of CEA (positive:>4 ㎍/ℓ. negative:<2.5㎍/ℓ) as golden data, the lung cancer was found in the image of PET-MRI, and then the SUVmax (positive:>4, negative:<1.5) was measured, and then evaluated the correlation and significance of results of relative diagnostic performance of PET-MRI compared to CEA through the statistical verification (t-test, P>0.05). Through this, the PET-MRI was analyzed as 96.29% of sensitivity, 95.23% of specificity, 3.70% of false negative rate, 4.76% of false positive rate, and 95.75% of accuracy. The false negative rate was 1.06% lower than the false positive rate. The PET-MRI that significant accuracy of diagnosis through high sensitivity and specificity, and low false negative rate and false positive rate of lung cancer, could acquire the fusion image of specialized soft tissue by combining the radio-pharmaceuticals with various sequences, so its clinical value and usefulness are regarded as latently sufficient.
Abstract
The results of empirical researches on the diagnosis of lung cancer are insufficient, so it is limited to objectively judge the clinical possibility and utilization according to the accuracy of diagnosis. Thus, this study retrospectively analyzed the lung cancer diagnostic performance of PET-MRI (Positron Emission Tomography-Magnetic Resonance Imaging) by using the decision matrix. This study selected and experimented total 165 patients who received both hematological CEA (Carcinoembryonic Antigen) test and hybrid PET-MRI (18F-FDG, 5.18 MBq/㎏ / Body TIM coil. VIVE-Dixon). After setting up the result of CEA (positive:>4 ㎍/ℓ. negative:<2.5㎍/ℓ) as golden data, the lung cancer was found in the image of PET-MRI, and then the SUVmax (positive:>4, negative:<1.5) was measured, and then evaluated the correlation and significance of results of relative diagnostic performance of PET-MRI compared to CEA through the statistical verification (t-test, P>0.05). Through this, the PET-MRI was analyzed as 96.29% of sensitivity, 95.23% of specificity, 3.70% of false negative rate, 4.76% of false positive rate, and 95.75% of accuracy. The false negative rate was 1.06% lower than the false positive rate. The PET-MRI that significant accuracy of diagnosis through high sensitivity and specificity, and low false negative rate and false positive rate of lung cancer, could acquire the fusion image of specialized soft tissue by combining the radio-pharmaceuticals with various sequences, so its clinical value and usefulness are regarded as latently sufficient.
참고문헌 (46)
- Annual report of cancer statistics in Korea in 2018, "Korea Central Cancer Registry", ~ (2021)
- 박지영, "Epidemiology of Lung Cancer in Korea: Recent Trends", Tuberculosis and Respiratory Diseases, 79(2), pp.58~69 (2016), 대한결핵및호흡기학회
- Papadopoulos A, "Heavy smoking and lung cancer : Are women at higher risk? Result of the ICARE study", Brt J Cancer, 110, pp.1385~1391 (2014)
- McLean AEB, "Diagnosing lung cancer : The complexities of obtaining a tissue diagnosis in the era of minimally invasive and personalised medicine", J Clin Med, 7(7), pp.163~ (2018)
- RiihimLki M, "Metastatic sites and survival in lung cancer", Lung Cancer, 86(1), pp.78~84 (2014)
- Conti M, "The new opportunities for high time resolution clinical TOF PET", Clin Trans Img, 7(2), pp.139~147 (2019)
- Erdi YE, "Limits of tumor detectability in nuclear medicine and PET", Mol Img Radionucl Ther, 21(1), pp.23~28 (2012)
- Qu X, "A meta-analysis of 18FDG-PET-CT, 18FDG-PET, MRI and bone scintigraphy for diagnosis of bone metastases in patients with lung cancer", Eur J Radiol, 81(5), pp.1007~1015 (2012)
- 이수진, "Usefulness of Integrated PET", MRI in Head and Neck Cancer: A Preliminary Study, 2014, pp.48(2), 98~105[DOI]
- Khiewvan B, "Update of the role of PET", CT and PET, Hell J Nucl Med, pp.2016, 19(3)[DOI]
- Ehman EC, "PET", MRI: Where might it replace PET, J Magn Reson Imaging, pp.2017, 46(5)[DOI]
- 권현우, "FDG Whole-Body PET", MRI in Oncology: a Systematic Review, 2017, pp.51(1), 22~31[DOI]
- Delso G, "PET", MRI system design, 2009, pp.36, 86~92
- 정진호, "PET", MRI: Technical Challenges and Recent Advances, 2016, pp.50(1), 3~12[DOI]
- Loeffelbein DJ, "PET-MRI fusion in head and neck oncology : Current status and implications for hybrid PET", MRI, 2012, pp.70(2), 473~483
- Nensa F, "Clinical applications of PET", MRI : current status and future perspectives, 2014, pp.20(5), 438~447
- Duan XY, "Predictive significance of standardized uptake value parameters of FDG-PET in patients with non-small cell lung carcinoma", Braz J Med Biol Res, 48(3), pp.267~272 (2015)
- BLsing KA, "Impact of blood glucose, diabetes, insulin, and obesity on standardized uptake values in tumors and healthy organs on 18F-FDG PET", CT, 2013, pp.40, 206~213
- Malladi A, "PET", CT mediastinal and liver FDG uptake : Effects of biological and procedural factors, 2013, pp.57, 169~175
- 김미영, "유방암에서 18F-FDG PET", CT의 pSUV와 병리학적 진단과의 연관성, 2013, pp.36(4), 305~311[DOI]
- Martinez-Moller A, "Tissue classification as a potential approach for attenuation correction in whole-body PET-MRI", J Nucl Med, 50, pp.520~526 (2009)
- Catana C, "Toward implementing an MRI-based PET attenuation-correction method for neurologic studies on the MR-PET brain prototype", J Nucl Med, 51, pp.1431~1438 (2010)
- Soongsathitanon S, "A new standardized uptake values(SUV)calculation based on pixel intensity values", Math Comput Simul, 6, pp.26~33 (2012)
- Franklin WA, "Abeloff's Clinical Oncology, Chap 15" (2020), Elsevier
- Jain S, "Henry's Clinical Diagnosis and Management by Laboratory Methods, Chap 74" (2017), Elsevier
- Boellaard R, "Effects of noise, image resolution, and ROI definition on the accuracy of standard uptake values : A simulation study", J Nucl Med, 45(9), pp.1519~1527 (2004)
- 김진의, "Evaluation of the Liver Cancer Diagnosis Function of PET-MRI Based on Decision Matrix Analysis", 한국콘텐츠학회 논문지, 17(11), pp.50~59 (2017), 한국콘텐츠학회[DOI]
- Kang GW, "Koh’s nuclear medicine", Kor Med, (3), pp.8~20 (2008)
- Hutton BF, "Advances in clinical molecular imaging instrumentation", Clin Transl Imaging, 6, pp.31~35 (2018)
- Cangemi V, "Assessment of the accuracy of diagnostic chest CT scanning. Impact on lung cancer management", Int Surg, 81(1), pp.77~82 (1996)
- Ambrosini V, "PET", CT imaging in different types of lung cancer : An overview, 2021, pp.81(5), 988~1001
- Silvestri GA, "Methods for staging non-small cell lung cancer", Chest J, 143(5), pp.211~250 (2013)
- Collins LG, "Lung cancer : Diagnosis and management", Am Fam Physician, 75(1), pp.56~63 (2007)
- Rivera MP, "Diagnosis of lung cancer* The guidelines", Chest, 123, pp.129~136 (2003)
- 신규설, "PET-CT에서 CT의 관전압 및 관전류에 따른 SUV값의 변화", 방사선기술과학, 30(4), pp.373~379 (2007), 대한방사선과학회
- Pournazari K, "Mehdizadeh Seraj S, Khosravi M, Arani L, Torigian D, et al. PET", MRI applications in lung cancer, 2018, pp.59(Supplement 1), 1157~
- Mayerhoefer ME, "PET", MRI versus PET, Eur J Nucl and Mol Img, pp.2020, 47[DOI]
- Hartenbach M, "Combined PET", MRI improves diagnostic accuracy in patients with prostate cancer : A prospective diagnostic trial, 2014, pp.20(12), 3244~3253
- Grunnet M, "Carcinoembryonic antigen(CEA)as tumor marker in lung cancer", Lung Cancer, 76(2), pp.138~143 (2012)
- Hsu WH, "Preoperative serum carcinoembryonic antigen level is a prognostic factor in women with early non-small-cell lung cancer", Ann Thorac Surg, 83(2), pp.419~424 (2007)
- Matsuoka K, "Prognostic value of carcinoembryonic antigen and CYFRA21-1 in patients with pathological stage I non-small cell lung cancer", Eur J Cardiothorac Surg, 32(3), pp.435~439 (2007)
- Okada M, "Effect of histologic type and smoking status on interpretation of serum carcinoembryonic antigen value in non-small cell lung carcinoma", Ann Thorac Surg, 78(3), pp.1004~1009 (2004)
- Okada M, "Prognostic significance of perioperative serum carcinoembryonic antigen in non-small cell lung cancer : Analysis of 1, 000 consecutive resections for clinical stage I disease", Ann Thorac Surg, 78(1), pp.216~221 (2004)
- Vickers AJ, "Decision analysis for the evaluation of diagnostic tests, prediction models and molecular markers", Am Stat, 62(4), pp.314~320 (2008)
- Killeen PR, "Beyond statistical inference : A decision theory for science", Psychon Bull Rev, 13(4), pp.549~562 (2006)
- Kubota K, "Differential diagnosis of lung tumor with positron emission tomography:A prospective study", J Nucl Med, 31(12), pp.1927~1932 (1990)